#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3164	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2741	341.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1719	1719	C	457	C	412	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4554	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4022	337.8	0	.	n	.	0	T695C	SNP	695	695	T	1315	1315	C	310	C,A	276,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4554	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4022	337.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1957	1957	A	406	A	371	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4554	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4022	337.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2591	2591	C	420	C	380	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4554	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4022	337.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3217	3217	T	397	T	353	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4554	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4022	337.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2665	2665	A	436	A	404	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	462	folP	852	852	100.0	folP.l15.c4.ctg.1	2043	67.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1222	1224	AGC	103;103;102	A;G;C	89;95;96	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	978	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3774	77.3	1	SNP	p	S91F	0	.	.	271	273	TCC	779	781	TCC	92;93;92	T;C;C,A	84;83;83,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	978	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3774	77.3	1	SNP	p	D95G	0	.	.	283	285	GAC	791	793	GAC	91;90;90	G;A;C	84;83;82	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	978	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3774	77.3	1	SNP	p	D95N	0	.	.	283	285	GAC	791	793	GAC	91;90;90	G;A;C	84;83;82	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	396	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1777	66.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	286	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1430	59.9	0	.	n	.	0	C187G	SNP	187	187	C	772	772	G	104	G	89	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1104	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3409	96.6	1	SNP	p	D86N	0	.	.	256	258	GAC	774	776	GAC	128;129;129	G;A;C	109;110;112	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1104	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3409	96.6	1	SNP	p	S87R	0	.	.	259	261	AGT	777	779	AGT	130;130;130	A,C;G;T,A	107,1;113;113,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1104	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3409	96.6	1	SNP	p	S87I	0	.	.	259	261	AGT	777	779	AGT	130;130;130	A,C;G;T,A	107,1;113;113,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1104	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3409	96.6	1	SNP	p	S87W	0	.	.	259	261	AGT	777	779	AGT	130;130;130	A,C;G;T,A	107,1;113;113,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1104	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3409	96.6	1	SNP	p	S88P	0	.	.	262	264	TCC	780	782	TCC	129;129;130	T;C;C	112;115;114	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	818	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3169	77.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1759	1761	GGC	96;95;95	G;G;C	89;82;86	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	756	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	77.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1506	1508	GCA	101;102;101	G;C;A	90;91;91	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	756	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	77.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1509	1511	ATC	100;100;100	A,C;T;C,A	92,1;86;87,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	756	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	77.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1521	1523	GTG	100;100;101	G;T;G,T	92;94;93,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	756	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	77.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1521	1523	GTG	100;100;101	G;T;G,T	92;94;93,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	756	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	77.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2025	2027	ACC	95;95;94	A,C;C;C	84,1;88;88	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	756	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	77.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2079	2081	GCG	98;98;99	G;C,A;G	87;76,1;76	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	756	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	77.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2079	2081	GCG	98;98;99	G;C,A;G	87;76,1;76	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	756	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	77.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2202	2204	GGC	88;88;89	G;G;C	72;72;75	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	756	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	77.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2211	2213	GGC	89;89;88	G;G;C	70;71;75	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	756	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2898	77.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2229	2231	CCG	88;89;89	C;C,G;G,C	73;74,1;73,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	996	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3570	83.4	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1825	1827	CTG	100;100;100	C;T;G	83;83;85	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	574	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2343	73.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	854	854	C	99	C	90	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	G38E	NONSYN	112	114	GGA	743	745	GAA	131;131;131	G;A;A	115;112;116	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	S46G	NONSYN	136	138	AGC	767	769	GGC	128;128;128	G;G;C	110;109;108	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	773	775	GGA	127;127;125	G;G;A	111;110;111	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	T87A	NONSYN	259	261	ACT	890	892	GCT	118;117;116	G;C,T;T,G	105;101,1;106,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	896	898	AGC	117;117;116	A,C;G;C	99,1;106;99	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	988	989	CG	118;119	C;G	106;109	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	991	993	CAG	119;119;117	C;A;G	109;111;107	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	995	997	AAA	119;118;119	A;A;A	108;109;107	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	1058	1060	GAA	114;115;115	G;A;A	107;108;106	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1082	1084	GCA	116;115;115	G;C;A	107;103;108	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	1190	1192	CGA	121;120;121	C;G;A	114;108;111	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1274	1276	ACT	127;127;126	A;C;T	117;116;111	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1277	1279	CAT	126;127;127	C;A,C;T	112;113,1;115	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1283	1285	ATG	126;126;126	A;T;G	116;115;113	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	.	MULTIPLE	766	767	AC	1397	1399	GCA	117;116;116	G;C;A	106;109;110	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	W257R	NONSYN	769	771	TGG	1401	1403	CGG	114;115;115	C;G;G	106;105;108	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	0	.	p	.	0	S258fs	FSHIFT	772	772	A	1404	1404	A	114	A	98	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	1	SNP	p	G120K	1	.	.	358	360	AAG	988	990	CGG	118;119;119	C;G;G	106;109;109	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	1	SNP	p	D121N	0	.	.	361	363	GAC	991	994	CGC	119;117;117	C;G;C	109;107;106	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	672	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	2021	98.2	1	SNP	p	A121D	1	.	.	361	363	GAC	991	994	CGC	119;117;117	C;G;C	109;107;106	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1890	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5398	104.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2275	2277	AAT	146;145;145	A;A;T	135;131;133	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	308	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1549	59.5	1	SNP	p	V57M	1	.	.	169	171	ATG	829	831	ATG	104;103;103	A;T;G	96;93;96	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
